1RC Stock Overview
Through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Creo Medical Group PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.19 |
| 52 Week High | UK£0.54 |
| 52 Week Low | UK£0.18 |
| Beta | 0.85 |
| 11 Month Change | -14.41% |
| 3 Month Change | -41.72% |
| 1 Year Change | -48.65% |
| 33 Year Change | -87.74% |
| 5 Year Change | -90.50% |
| Change since IPO | -78.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1RC | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.6% | 2.4% | 0.8% |
| 1Y | -48.6% | -5.0% | 9.1% |
Return vs Industry: 1RC underperformed the German Medical Equipment industry which returned -5% over the past year.
Return vs Market: 1RC underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| 1RC volatility | |
|---|---|
| 1RC Average Weekly Movement | 9.1% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1RC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1RC's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 278 | Craig Gulliford | www.creomedical.com |
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; SlypSeal Flex, an electrosurgical haemostasis device; and SpydrBlade Flex, a bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues.
Creo Medical Group PLC Fundamentals Summary
| 1RC fundamental statistics | |
|---|---|
| Market cap | €77.68m |
| Earnings (TTM) | -€26.83m |
| Revenue (TTM) | €36.30m |
2.1x
P/S Ratio-2.9x
P/E RatioIs 1RC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1RC income statement (TTM) | |
|---|---|
| Revenue | UK£30.30m |
| Cost of Revenue | UK£15.30m |
| Gross Profit | UK£15.00m |
| Other Expenses | UK£37.40m |
| Earnings | -UK£22.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.056 |
| Gross Margin | 49.50% |
| Net Profit Margin | -73.93% |
| Debt/Equity Ratio | 30.0% |
How did 1RC perform over the long term?
See historical performance and comparison